Holen Sie sich die Stockscreener-App
6.93
1.98%
-0.14
Handel nachbörslich:
6.90
-0.03
-0.43%
Regenxbio Inc Aktie (RGNX) Neueste Nachrichten
REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy - Eastern Progress
Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Eastern Progress
FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy - Stocktwits
Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax - Barchart.com
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $26 - Moomoo
H.C. Wainwright lowers Regenxbio stock price target on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright lowers Regenxbio stock price target on trial data - Investing.com
Analysts Are Bullish on Top Healthcare Stocks: RegenXBio (RGNX), Climb Bio (CLYM) - The Globe and Mail
Understanding Momentum Shifts in (RGNX) - Stock Traders Daily
JPMorgan Chase & Co. Reduces Stake in Regenxbio Inc. - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
RGNX Maintains Rating by HC Wainwright & Co. -- Price Target Low - GuruFocus
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $26 - Moomoo
RGNX Maintains Rating by HC Wainwright & Co. -- Price Target Lowered to $26 - GuruFocus
Regenxbio slides after late-stage trial data for Duchenne therapy - MSN
JPMorgan affiliates report 4.4% stake in REGENXBIO (RGNX) in 13G/A - Stock Titan
REGENXBIO (RGNX) offers exchange of 2.9M eligible options for replacements - Stock Titan
REGENXBIO (NASDAQ: RGNX) investors back board, reject executive option swap - Stock Titan
REGENXBIO (RGNX) awards director Daniel Tasse RSUs and options - Stock Titan
REGENXBIO (RGNX) director receives new RSU and stock option awards - Stock Titan
[Form 4] REGENXBIO Inc. Insider Trading Activity - Stock Titan
REGENXBIO (RGNX) director Kenneth Mills granted RSUs and 46,600 stock options - Stock Titan
REGENXBIO (RGNX) director awarded 9,807 RSUs and 46,600 stock options - Stock Titan
Director at REGENXBIO (RGNX) receives RSU and option grants - Stock Titan
REGENXBIO Inc. (RGNX) director receives new RSU and stock option grants - Stock Titan
Equity grants to REGENXBIO (NASDAQ: RGNX) director Jean Bennett - Stock Titan
How The REGENXBIO (RGNX) Investment Story Is Evolving Without New Analyst Commentary - Yahoo Finance
RGNX Should I Buy - Intellectia AI
RGNX stock on track for worst day ever as big Q1 loss, cash concerns eclipse Duchenne trial success - MSN
Regenxbio files $300M mixed shelf offering - MSN
REGENXBIO to push for accelerated approval of DMD gene therapy - MSN
Stifel reiterates Buy rating on Regenxbio stock ahead of trial data - Investing.com UK
Stifel reiterates Buy rating on Regenxbio stock ahead of trial data By Investing.com - Investing.com South Africa
Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Avoiding Lag: Real-Time Signals in (RGNX) Movement - Stock Traders Daily
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies - BioSpace
Morgan Stanley Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $6.25 - Moomoo
RGNX: Rolling BLA for Duchenne gene therapy set for Q3 2024, with robust data and regulatory momentum - TradingView
Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway - Insider Monkey
RegenXbio’s RGX-202 Pivotal Win Lifts Outlook - TipRanks
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):